Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTP-131 Safety and PK in Renal Impairment
NCT02436447Phase 1Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elamipretide in renal impairment (RI), sponsored by Stealth BioTherapeutics. Started May 2015; status: completed.
02
Drugs
elamipretide
03
Conditions
renal impairment (RI)
Beyond the preview
Go deeper on NCT02436447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436447.